SEHK:1696 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	495	48	N/A	N/A	1
12/31/2025	433	40	N/A	26	3
12/31/2024	384	33	N/A	23	3
6/30/2024	356	24	33	40	N/A
3/31/2024	358	28	34	42	N/A
12/31/2023	359	31	35	44	N/A
9/30/2023	355	35	-5	32	N/A
6/30/2023	352	38	-46	19	N/A
3/31/2023	353	39	-44	21	N/A
12/31/2022	354	40	-42	22	N/A
9/30/2022	349	38	-11	22	N/A
6/30/2022	344	35	19	22	N/A
3/31/2022	319	33	24	27	N/A
12/31/2021	294	31	29	32	N/A
9/30/2021	255	28	35	40	N/A
6/30/2021	216	24	42	47	N/A
3/31/2021	189	19	29	36	N/A
12/31/2020	162	13	16	26	N/A
9/30/2020	161	13	10	19	N/A
6/30/2020	160	13	4	12	N/A
3/31/2020	167	17	11	17	N/A
12/31/2019	174	21	18	21	N/A
9/30/2019	167	22	19	21	N/A
6/30/2019	161	24	19	22	N/A
3/31/2019	158	23	17	19	N/A
12/31/2018	154	22	15	16	N/A
9/30/2018	151	18	13	14	N/A
6/30/2018	149	14	10	11	N/A
3/31/2018	143	12	N/A	14	N/A
12/31/2017	137	11	N/A	17	N/A
9/30/2017	131	11	N/A	18	N/A
6/30/2017	126	10	N/A	19	N/A
3/31/2017	123	11	N/A	20	N/A
12/31/2016	118	8	N/A	16	N/A
12/31/2015	110	8	N/A	16	N/A
12/31/2014	101	6	N/A	23	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1696's forecast earnings growth (26.5% per year) is above the savings rate (2.3%).

Earnings vs Market: 1696's earnings (26.5% per year) are forecast to grow faster than the Hong Kong market (11.6% per year).

High Growth Earnings: 1696's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1696's revenue (12.8% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 1696's revenue (12.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1696's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 15:12
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sisram Medical Ltd is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yuan Gao	China International Capital Corporation Limited
Yifan Du	Citic Securities Co., Ltd.
Eugene Huang	Jefferies LLC

Sisram Medical Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

Sisram Medical Ltd Provides Earnings Guidance for the Year Ending December 31, 2021

Sisram Medical Ltd Provides Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

Investors Could Be Concerned With Sisram Medical's (HKG:1696) Returns On Capital

Sisram Medical Ltd Announces the Launch of the Latest Edition of Alma Harmony

Sisram Medical Ltd Announces Appointment of Jiahong LI New Chief Financial Officer, Effective 29 October 2024

What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 24%

Sisram Medical Ltd Receives Product Approval from the National Medical Products Administration

First half 2024 earnings released: EPS: US$0.023 (vs US$0.04 in 1H 2023)

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Dividend of HK$0.16 announced

Sisram Medical Ltd to Report First Half, 2024 Results on Aug 21, 2024

Sisram Medical Ltd Declares A Final Dividend, Payable on or Around 9 September 2024

Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Sisram Medical Ltd, Annual General Meeting, Jun 24, 2024

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Sisram Medical Ltd Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2023

Sisram Medical Ltd to Report Fiscal Year 2023 Results on Mar 20, 2024

Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Investor sentiment deteriorates as stock falls 20%

Now 21% overvalued

Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Sisram Medical Ltd Announces the Registration Application of Profhilo

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 19%

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

First half 2023 earnings released: EPS: US$0.04 (vs US$0.044 in 1H 2022)

Upcoming dividend of HK$0.17 per share at 2.3% yield

Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Sisram Medical Ltd Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable 07 September 2023

Sisram Medical Announces the Launch of Alma Veil for the U.S. Market

Sisram Medical Ltd. Receives the Clearance from the U.S. Food and Drug Administration

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 16%

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

Sisram Medical Ltd, Annual General Meeting, Jun 28, 2023

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.086 (vs US$0.069 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Sisram Medical Ltd Announces Resignation of Mr. Guojun Bu from the Position of Executive Director of the Company with Effect from January 1, 2023

Investor sentiment improved over the past week

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Less than half of directors are independent

Investor sentiment improved over the past week

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Investor sentiment deteriorated over the past week

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

First half 2022 earnings released: EPS: US$0.044 (vs US$0.037 in 1H 2021)

Sisram Medical Ltd SHARE to Be Deleted from OTC Equity

Upcoming dividend of HK$0.16 per share

Sisram Medical Ltd to Report Q2, 2022 Results on Aug 19, 2022

Sisram Medical Ltd Declares Final Dividend for the Year Ended December 31, 2021, Payable on or Around 2 September 2022

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Investor sentiment deteriorated over the past week

Sisram Medical Ltd Announces Phase IIb Clinical Result on Submental Fat Reduction of JS-001

Investor sentiment improved over the past week

Investor sentiment improved over the past week